,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11111154,5816,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,410,1,5,,11111154,5816,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
2,411,2,1,,11111154,5816,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
3,444,1,1,,11111154,5816,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
4,445,3,1,,11111154,5816,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
5,446,1,1,,11111154,5816,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
6,447,1,1,,11111154,5816,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
7,448,1,2,,11111154,5816,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
8,450,1,2,,11111154,5816,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
9,451,1,2,,11111154,5816,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
10,526,1,1,,11111154,5816,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
11,530,1,1,,11111154,5816,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
12,584,1,3,,11111154,5816,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
13,585,1,4,,11111154,5816,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
14,587,1,5,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
15,588,1,4,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
16,589,1,3,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
17,590,1,3,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
18,591,1,4,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
19,592,1,6,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
20,593,1,4,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
21,594,1,4,,11111154,5816,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
22,595,1,3,,11111154,5816,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
23,596,1,2,,11111154,5816,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
24,597,1,3,,11111154,5816,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
25,603,1,2,,11111154,5816,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
26,605,1,2,,11111154,5816,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
27,607,1,3,,11111154,5816,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
28,662,1,1,,11111154,5816,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
29,875,1,2,,11111154,5816,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
30,875,1,2,,26754418,5816,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
31,879,1,2,,11111154,5816,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
32,879,1,2,,11111154,5816,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
33,880,2,1,,26754418,5816,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
34,880,2,1,,26754418,5816,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
35,880,2,1,,26754419,5816,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
36,880,2,1,,26754419,5816,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
37,880,2,1,,29215202,5816,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
38,880,2,1,,29215202,5816,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
39,881,2,2,,11111154,5816,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
40,881,2,2,,26754418,5816,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
41,881,2,2,,29215202,5816,Inactive,317373425.0,247.0,14.1254,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
42,883,1,3,,11111154,5816,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
43,884,1,2,,11111154,5816,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
44,884,1,2,,26754418,5816,Inconclusive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
45,885,1,2,,11111154,5816,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
46,885,1,2,,26754418,5816,Inactive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
47,886,1,2,,11111154,5816,Active,122921310.0,,0.7943,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
48,886,1,2,,11111154,5816,Active,122921311.0,,0.7943,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
49,887,1,2,,11111154,5816,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
50,887,1,2,,26754418,5816,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
51,889,1,3,,11111154,5816,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
52,889,1,3,,26754418,5816,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
53,891,1,2,,11111154,5816,Inconclusive,40805836.0,1565.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
54,892,1,2,,11111154,5816,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
55,892,1,2,,26754418,5816,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
56,893,1,2,,11111154,5816,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
57,893,1,2,,11111154,5816,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
58,893,1,2,,26754418,5816,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
59,893,1,2,,26754418,5816,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
60,894,2,1,,26754418,5816,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
61,894,2,1,,29215202,5816,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
62,895,1,2,,11111154,5816,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
63,899,1,2,,11111154,5816,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
64,900,1,3,,11111154,5816,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
65,900,1,3,,26754418,5816,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
66,901,1,2,,11111154,5816,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
67,901,1,2,,26754418,5816,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
68,902,1,2,,11111154,5816,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
69,902,1,2,,26754418,5816,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
70,912,1,2,,11111154,5816,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
71,914,1,3,,11111154,5816,Inconclusive,32879895.0,3091.0,1.5849,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
72,915,1,3,,11111154,5816,Active,32879895.0,3091.0,1.5849,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
73,917,1,3,,11111154,5816,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
74,918,1,3,,11111154,5816,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
75,923,1,2,,11111154,5816,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
76,923,1,2,,26754418,5816,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
77,924,1,2,,11111154,5816,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
78,924,1,2,,26754418,5816,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
79,925,1,2,,11111154,5816,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
80,926,1,2,,11111154,5816,Inconclusive,38016895.0,7253.0,31.6228,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
81,927,1,3,,11111154,5816,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
82,928,1,2,,11111154,5816,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
83,938,1,2,,11111154,5816,Inconclusive,38016895.0,7253.0,31.6228,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
84,943,1,2,,11111154,5816,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
85,944,1,2,,11111154,5816,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
86,945,1,4,,11111154,5816,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
87,954,1,2,,11111154,5816,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
88,957,1,2,,11111154,5816,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
89,958,1,2,,11111154,5816,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
90,959,1,4,,11111154,5816,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
91,992,1,3,,11111154,5816,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
92,995,1,2,,11111154,5816,Inconclusive,66932916.0,5594.0,3.9811,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
93,995,1,2,,26754418,5816,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
94,997,1,2,,11111154,5816,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
95,998,1,2,,11111154,5816,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
96,1030,2,1,,26754418,5816,Inconclusive,30582681.0,216.0,14.1254,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
97,1030,2,1,,26754419,5816,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
98,1030,2,1,,29215202,5816,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
99,1195,1,2,,48415945,5816,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
100,1379,1,2,,26754418,5816,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
101,1379,1,2,,29215202,5816,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
102,1452,1,1,,11111154,5816,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
103,1452,1,1,,26754418,5816,Inactive,154426292.0,239.0,28.1838,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
104,1452,1,1,,29215202,5816,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
105,1454,1,1,,26754418,5816,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
106,1457,1,1,,26754418,5816,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
107,1457,1,1,,26754419,5816,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
108,1457,1,1,,29215202,5816,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
109,1458,1,1,,26754419,5816,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
110,1460,1,3,,26754418,5816,Active,92096784.0,4137.0,7.9433,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
111,1460,1,3,,26754419,5816,Inconclusive,92096784.0,4137.0,11.2202,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
112,1460,1,3,,29215202,5816,Active,92096784.0,4137.0,14.1254,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
113,1463,1,1,,26754418,5816,Inconclusive,,,14.1254,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
114,1463,1,1,,26754419,5816,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
115,1463,1,1,,29215202,5816,Inconclusive,,,15.8489,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
116,1467,1,3,,26754418,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
117,1467,1,3,,29215202,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
118,1468,1,1,,26754418,5816,Active,92096784.0,4137.0,12.5893,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
119,1468,1,1,,26754419,5816,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
120,1468,1,1,,29215202,5816,Inconclusive,92096784.0,4137.0,14.1254,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
121,1469,1,1,,26754418,5816,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
122,1469,1,1,,26754419,5816,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
123,1469,1,1,,26754420,5816,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
124,1469,1,1,,29215202,5816,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
125,1471,2,1,,11111154,5816,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
126,1471,2,1,,26754418,5816,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
127,1471,2,1,,26754419,5816,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
128,1471,2,1,,29215202,5816,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
129,1476,2,1,,26754418,5816,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
130,1476,2,1,,29215202,5816,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
131,1477,1,1,,26754418,5816,Inconclusive,,,19.9526,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
132,1477,1,1,,26754419,5816,Inconclusive,,,7.9433,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
133,1477,1,1,,29215202,5816,Inconclusive,,,39.8107,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
134,1478,2,1,,26754418,5816,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
135,1478,2,1,,29215202,5816,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
136,1479,1,2,,26754418,5816,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
137,1479,1,2,,26754419,5816,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
138,1479,1,2,,26754420,5816,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
139,1479,1,2,,29215202,5816,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
140,1487,1,1,,29215202,5816,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
141,1490,2,1,,26754418,5816,Active,10954339.0,,50.1187,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
142,1490,2,1,,26754419,5816,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
143,1490,2,1,,26754420,5816,Inconclusive,10954339.0,,7.0795,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
144,1490,2,1,,29215202,5816,Active,10954339.0,,25.1189,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
145,1519,1,3,,26754418,5816,Inconclusive,,,14.1254,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
146,1688,1,1,,29215202,5816,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
147,1766,1,1,,26754418,5816,Inconclusive,18860839.0,4221.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
148,1766,1,1,,26754418,5816,Inconclusive,56550039.0,4297.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
149,1766,1,1,,26754420,5816,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
150,1766,1,1,,26754420,5816,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
151,1766,1,1,,29215202,5816,Inconclusive,18860839.0,4221.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
152,1766,1,1,,29215202,5816,Inconclusive,56550039.0,4297.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
153,1768,1,1,,26754418,5816,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
154,1768,1,1,,26754418,5816,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
155,1768,1,1,,26754420,5816,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
156,1768,1,1,,26754420,5816,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
157,1768,1,1,,29215202,5816,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
158,1768,1,1,,29215202,5816,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
159,1851,1,2,,11111154,5816,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
160,1851,1,2,1.0,11111154,5816,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
161,1851,1,2,2.0,11111154,5816,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
162,1851,1,2,3.0,11111154,5816,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
163,1851,1,2,4.0,11111154,5816,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
164,1851,1,2,5.0,11111154,5816,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
165,1865,1,1,,26754418,5816,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
166,1865,1,1,,26754419,5816,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
167,1865,1,1,,29215202,5816,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
168,1948,1,1,,26754418,5816,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
169,1948,1,1,,29215202,5816,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
170,2101,1,1,,26754418,5816,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
171,2101,1,1,,26754419,5816,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
172,2101,1,1,,26754420,5816,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
173,2101,1,1,,29215202,5816,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
174,2107,1,1,,26754418,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
175,2107,1,1,,26754419,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
176,2107,1,1,,26754420,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
177,2107,1,1,,29215202,5816,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
178,2112,1,1,,26754418,5816,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
179,2112,1,1,,26754419,5816,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
180,2112,1,1,,26754420,5816,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
181,2112,1,1,,29215202,5816,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
182,2147,1,1,,26754418,5816,Active,221046486.0,,7.0795,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
183,2314,1,2,,26754420,5816,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
184,2314,1,2,,26754420,5816,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
185,2314,1,2,,29215202,5816,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
186,2314,1,2,,29215202,5816,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
187,2315,1,2,,26754420,5816,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
188,2315,1,2,,26754420,5816,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
189,2315,1,2,,29215202,5816,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
190,2315,1,2,,29215202,5816,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
191,2451,1,2,,26754418,5816,Active,122920737.0,,11.1936,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
192,2451,1,2,,26754420,5816,Active,122920737.0,,11.1936,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
193,2451,1,2,,29215202,5816,Active,122920737.0,,17.7407,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
194,2472,1,2,,26754418,5816,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
195,2472,1,2,,26754420,5816,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
196,2472,1,2,,29215202,5816,Active,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
197,2517,2,1,,26754418,5816,Active,6980812.0,,3.5481,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
198,2517,2,1,,26754419,5816,Inconclusive,6980812.0,,8.9125,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
199,2517,2,1,,26754420,5816,Active,6980812.0,,7.9433,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
200,2517,2,1,,144205115,5816,Inconclusive,6980812.0,,35.4813,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
201,2528,1,2,,26754418,5816,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
202,2528,1,2,,26754420,5816,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
203,2528,1,2,,29215202,5816,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
204,2546,1,1,,26754418,5816,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
205,2546,1,1,,26754420,5816,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
206,2546,1,1,,29215202,5816,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
207,2549,1,1,,26754418,5816,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
208,2549,1,1,,26754419,5816,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
209,2549,1,1,,26754420,5816,Active,282403581.0,,17.7828,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
210,2549,1,1,,29215202,5816,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
211,2551,1,1,,26754418,5816,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
212,2551,1,1,,26754420,5816,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
213,2551,1,1,,29215202,5816,Inconclusive,188536040.0,19885.0,0.5623,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
214,2564,1,1,,26754418,5816,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Assay,Confirmatory,,
215,2564,1,1,,29215202,5816,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Assay,Confirmatory,,
216,2565,1,1,,26754418,5816,Inactive,405898.0,,14.1254,Potency,Counterscreen for APE1 Inhibitors: qHTS Assay for Inhibitors of Endonuclease IV,Confirmatory,,
217,2565,1,1,,29215202,5816,Inactive,405898.0,,4.4668,Potency,Counterscreen for APE1 Inhibitors: qHTS Assay for Inhibitors of Endonuclease IV,Confirmatory,,
218,2572,1,1,,26754418,5816,Inactive,6980812.0,,,Potency,Confirmation qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
219,2572,1,1,,29215202,5816,Inconclusive,6980812.0,,5.0119,Potency,Confirmation qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
220,2573,1,1,,26754418,5816,Inactive,6980812.0,,,Potency,qHTS FP-Based Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
221,2573,1,1,,29215202,5816,Inactive,6980812.0,,,Potency,qHTS FP-Based Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
222,2660,1,1,,90341589,5816,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
223,2662,2,1,,29215202,5816,Inconclusive,56550039.0,4297.0,39.8107,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
224,2666,1,1,,90341589,5816,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
225,2667,1,1,,90341589,5816,Active,4826730.0,2475.0,26.1216,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
226,2668,1,1,,90341589,5816,Inconclusive,4826730.0,2475.0,23.2809,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
227,2708,1,1,,26754420,5816,Inconclusive,282403581.0,,112.20200000000001,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
228,2711,1,1,,26754420,5816,Active,,,14.1254,Potency,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
229,2712,1,1,,26754420,5816,Active,,,14.1254,Potency,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
230,18736,3,3,,103190535,5816,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membrane without any host,Other,10476872.0,
231,18737,3,3,,103190535,5816,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid decyl ester polymer,Other,10476872.0,
232,18738,3,3,,103190535,5816,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid ethyl ester polymer,Other,10476872.0,
233,18739,3,3,,103190535,5816,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with (2-Butoxy-5-tert-butyl-3-methyl-phenyl)-methanol polymer,Other,10476872.0,
234,18740,3,3,,103190535,5816,Unspecified,,,,,"Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with 6,7,9,10,17,18,20,21-Octahydro-5,8,11,16,19,22-hexaoxa-dibenzo[a,j]cyclooctadecene",Other,10476872.0,
235,22293,4,4,,103190535,5816,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
236,23236,3,3,,103190535,5816,Unspecified,,,,,Partition coefficient (logP),Other,10476872.0,
237,26304,4,4,,103190535,5816,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
238,29359,3,3,,103190535,5816,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
239,29811,4,3,,103190535,5816,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
240,32954,9,5,,103190535,5816,Active,543734.0,24173.0,2.4,Ki,Displacement of [3H]WB-4101 from adrenergic alpha 1 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
241,32954,9,5,,103190535,5816,Active,1168244.0,29413.0,2.4,Ki,Displacement of [3H]WB-4101 from adrenergic alpha 1 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
242,32954,9,5,,103190535,5816,Active,1168247.0,29412.0,2.4,Ki,Displacement of [3H]WB-4101 from adrenergic alpha 1 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
243,32956,9,5,,103190535,5816,Active,231461.0,25083.0,0.038,Ki,Displacement of [3H]clonidine from adrenergic alpha 2 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
244,32956,9,5,,103190535,5816,Active,231464.0,24175.0,0.038,Ki,Displacement of [3H]clonidine from adrenergic alpha 2 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
245,32956,9,5,,103190535,5816,Active,47117345.0,24174.0,0.038,Ki,Displacement of [3H]clonidine from adrenergic alpha 2 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
246,33078,9,5,,103190535,5816,Active,114754.0,24925.0,1.2,Ki,Displacement of [3H]dihydroalprenolol from adrenergic beta 1 receptor of rat cerebral cortical membranes,Confirmatory,8254623.0,
247,33079,10,5,,103190535,5816,Active,114768.0,24176.0,0.72,Ki,Binding affinity against adrenergic beta 2 receptor versus 1 nM [3H]dihydroalprenolol in rat cerebral cerebellar membranes,Confirmatory,8254623.0,
248,33129,9,1,,103190535,5816,Active,,,0.017,IC50,Binding affinity against Alpha adrenergic receptor using [3H]dihydroergocryptine radioligand in rat brain homogenate,Confirmatory,7328588.0,
249,33140,3,8,,103190535,5816,Unspecified,,,,,Relative affinity for Alpha adrenergic receptor,Other,7328588.0,
250,35994,6,3,,103190535,5816,Active,,,0.4,EC50,Agonistic potency at alpha-1 adrenergic receptor for the amine-induced increase of phosphatidylinositol breakdown in synaptoneurosomes from guinea pig cerebral cortex,Confirmatory,2845082.0,
251,36054,11,1,,103190535,5816,Active,,,0.005,Ki,Binding affinity against alpha 2-Adrenergic receptor in guinea pig cerebral cortical membranes by displacement of [3H]clonidine,Confirmatory,2845082.0,
252,36103,9,1,,103190535,5816,Active,,,2.0,Ki,Binding affinity against alpha-1 adrenergic receptor in guinea pig cerebral cortical membranes by displacement of [3H]- WB-4101,Confirmatory,2845082.0,
253,36188,9,2,,103190535,5816,Active,,,0.008,IC50,Inhibition of [3H]p-aminoclonidine (PAC) binding to alpha-2 adrenergic receptor of purified human platelet plasma membranes,Confirmatory,3037080.0,
254,36352,6,8,,103190535,5816,Active,1351829.0,150.0,0.3,EC50,Agonistic potency at alpha 2-Adrenergic receptor for inhibition of 10 uM forskolin-elicited stimulation of adenylate cyclase in human platelet membranes,Confirmatory,2845082.0,
255,36352,6,8,,103190535,5816,Active,20141211.0,152.0,0.3,EC50,Agonistic potency at alpha 2-Adrenergic receptor for inhibition of 10 uM forskolin-elicited stimulation of adenylate cyclase in human platelet membranes,Confirmatory,2845082.0,
256,36352,6,8,,103190535,5816,Active,613504690.0,151.0,0.3,EC50,Agonistic potency at alpha 2-Adrenergic receptor for inhibition of 10 uM forskolin-elicited stimulation of adenylate cyclase in human platelet membranes,Confirmatory,2845082.0,
257,36435,4,7,,103190535,5816,Active,,,4.073,EC50,Effective dose for contraction of reserpine-pretreated rat vas deferens.,Confirmatory,7562902.0,
258,37459,9,2,,103190535,5816,Active,,,1.6,Ki,Binding of [3H]prazosin to alpha-1 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
259,37468,9,1,,103190535,5816,Active,,,0.2,Ki,Compound was evaluated for inhibition of [3H]prazosin binding to Alpha-1 adrenergic receptor in rat forebrain homogenate.,Confirmatory,7328589.0,
260,40408,9,2,,103190535,5816,Active,,,1.1,Ki,Binding of [3H]dihydroalprenolol to beta-1 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
261,40846,5,6,,103190535,5816,Active,81914759.0,100722663.0,0.015,EC50,Effective dose for relaxation of guinea pig trachea.,Confirmatory,7562902.0,
262,41478,9,2,,103190535,5816,Active,,,0.66,Ki,Binding of [3H]dihydroalprenolol to beta-2 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
263,41600,6,3,,103190535,5816,Active,,,0.23,EC50,Agonistic potency at beta adrenergic receptor for the stimulation of accumulation of cyclic AMP in cultured C6 glioma cells,Confirmatory,2845082.0,
264,41603,9,1,,103190535,5816,Active,,,29.0,IC50,Binding affinity against Beta adrenergic receptor using [3H]dihydroalprenolol radioligand in rat brain homogenate,Confirmatory,7328588.0,
265,41759,3,8,,103190535,5816,Unspecified,,,,,Relative affinity for Beta adrenergic receptor,Other,7328588.0,
266,42049,7,2,,103190535,5816,Active,,,0.26,EC50,Agonistic potency at beta-1 adrenergic receptor for the percent maximal increase in contraction rate of isolated guinea pig atria,Confirmatory,2845082.0,
267,42053,5,3,,103190535,5816,Active,,,0.015,EC50,Effective dose required to stimulate contractions in isolated guinea pig atrium.,Confirmatory,7562902.0,
268,42193,10,1,,103190535,5816,Active,,,3.0,Ki,Binding affinity against beta-1 adrenergic receptor in guinea pig cerebral cortical membranes by displacement of Dihydro-[3H]-alprenolol,Confirmatory,2845082.0,
269,44627,6,8,,103190535,5816,Active,114754.0,24925.0,0.23,EC50,Stimulation of cyclic AMP accumulation in C6 glioma cells expressing adrenergic beta receptor,Confirmatory,8254623.0,
270,44627,6,8,,103190535,5816,Active,114768.0,24176.0,0.23,EC50,Stimulation of cyclic AMP accumulation in C6 glioma cells expressing adrenergic beta receptor,Confirmatory,8254623.0,
271,44627,6,8,,103190535,5816,Active,543882.0,25645.0,0.23,EC50,Stimulation of cyclic AMP accumulation in C6 glioma cells expressing adrenergic beta receptor,Confirmatory,8254623.0,
272,48327,6,1,,103190535,5816,Unspecified,,,,,Effect on increase in heart rate in anesthetized cats at intravenous dose of 1.0 ug/kg,Other,6319700.0,
273,48329,6,1,,103190535,5816,Unspecified,,,,,Effect on increase in heart rate in anesthetized cats at intravenous dose of 2.0 ug/kg,Other,6319700.0,
274,50067,3,3,,103190535,5816,Unspecified,,,,,Effect on rise in arterial pressure in anesthetized cats at intravenous dose of 1.0 ug/kg,Other,6319700.0,
275,50070,3,3,,103190535,5816,Unspecified,,,,,Effect on rise in arterial pressure in anesthetized cats at intravenous dose of 2.0 ug/kg,Other,6319700.0,
276,61865,8,5,,103190535,5816,Unspecified,118228.0,1812.0,55.0,Kd,Equilibrium dissociation constant against recombinant Dopamine receptor D1A expressed in COS7 cells,Confirmatory,8632409.0,
277,61867,3,9,,103190535,5816,Unspecified,118228.0,1812.0,,,log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell,Other,8632409.0,
278,61996,3,9,,103190535,5816,Active,118229.0,24316.0,,,Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A,Other,8632409.0,
279,64788,3,9,,103190535,5816,Unspecified,47117674.0,24318.0,,,Low-affinity agonist dissociation constant against striatal Dopamine receptor D2,Other,8632409.0,
280,70530,3,3,,103190535,5816,Unspecified,,,,,Free energy of binding to turkey erythrocyte beta receptor,Other,3005570.0,
281,73730,6,2,,103190535,5816,Active,,,0.4,EC50,Effective concentration for stimulation of [3H]phosphoinositide formation in guinea pig synaptoneurosomes expressing alpha-1 receptor,Confirmatory,8254623.0,
282,141655,11,1,,103190535,5816,Active,,,4.0,Ki,Compound was evaluated for binding affinity towards mu-specific opiate receptor from combinatorial peptoid library,Confirmatory,8064796.0,
283,171643,3,4,,103190535,5816,Unspecified,,,,,Change in diastolic blood pressure after iv administration of 1 mg/kg in anesthetized rats,Other,10447956.0,
284,171676,3,4,,103190535,5816,Unspecified,,,,,Change in systolic blood pressure after iv administration of 1 mg/kg in anesthetized rats,Other,10447956.0,
285,192743,3,3,,103190535,5816,Unspecified,,,,,Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 1 mg/kg in anesthetized rats,Other,10447956.0,
286,193762,6,1,,103190535,5816,Unspecified,,,,,Change in heart rate after iv administration of 1 mg/kg in anesthetized rats,Other,10447956.0,
287,215613,3,3,,103190535,5816,Unspecified,,,,,Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly Beta adrenergic receptor was determined,Other,7154001.0,
288,218846,3,7,,103190535,5816,Inconclusive,,,,,Compound was evaluated for change in Gibb's free energy at Low affinity beta2- adrenoceptor in the membranes of bovine skeletal muscle preparation; Not determined,Other,2836587.0,
289,218847,4,6,,103190535,5816,Unspecified,,,,,Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.,Other,2836587.0,
290,218848,4,6,,103190535,5816,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells,Other,2836587.0,
291,219797,9,2,,103190535,5816,Active,,,0.013000000000000001,Ki,Binding of [3H]clonidine to alpha-2-adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
292,231532,3,4,,103190535,5816,Unspecified,,,,,Ratio of binding affinity towards alpha1 to alpha-2 receptor,Other,2845082.0,
293,293045,7,1,,103190535,5816,Unspecified,115449.0,759.0,,,Activity of human recombinant CA1 at 10 uM by stopped-flow technique,Other,17127057.0,
294,293046,7,1,,103190535,5816,Unspecified,115456.0,760.0,,,Activity of human recombinant CA2 at 10 uM by stopped-flow technique,Other,17127057.0,
295,293047,7,1,,103190535,5816,Unspecified,115465.0,762.0,,,Activity of human recombinant CA4 at 10 uM by stopped-flow technique,Other,17127057.0,
296,293048,7,1,,103190535,5816,Unspecified,461680.0,763.0,,,Activity of human recombinant CA5A at 10 uM by stopped-flow technique,Other,17127057.0,
297,293049,7,1,,103190535,5816,Unspecified,1168744.0,766.0,,,Activity of human recombinant CA7 at 10 uM by stopped-flow technique,Other,17127057.0,
298,293050,7,1,,103190535,5816,Unspecified,8928036.0,23632.0,,,Activity of human recombinant CA14 at 10 uM by stopped-flow technique,Other,17127057.0,
299,293051,7,1,,103190535,5816,Active,115449.0,759.0,,,Activation of human recombinant CA1 by CO2 hydration method,Other,17127057.0,
300,293052,7,1,,103190535,5816,Unspecified,115456.0,760.0,,,Activation of human recombinant CA2 by CO2 hydration method,Other,17127057.0,
301,293053,7,1,,103190535,5816,Active,115465.0,762.0,,,Activation of human recombinant CA4 by CO2 hydration method,Other,17127057.0,
302,293054,7,1,,103190535,5816,Unspecified,461680.0,763.0,,,Activation of human recombinant CA5A by CO2 hydration method,Other,17127057.0,
303,293055,7,1,,103190535,5816,Unspecified,1168744.0,766.0,,,Activation of human recombinant CA7 by CO2 hydration method,Other,17127057.0,
304,293056,7,1,,103190535,5816,Active,8928036.0,23632.0,,,Activation of human recombinant CA14 by CO2 hydration method,Other,17127057.0,
305,294856,3,3,,103190535,5816,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,17336075.0,
306,326592,5,6,,103190535,5816,Active,461604.0,155.0,0.031,EC50,Agonist activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels by DELFIA method,Confirmatory,18083578.0,
307,326593,3,10,,103190535,5816,Unspecified,461604.0,155.0,,,Intrinsic activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels relative to R-(-)-isoproterenol,Other,18083578.0,
308,326595,5,6,,103190535,5816,Active,461604.0,155.0,0.049,EC50,Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as [3H]cAMP levels by radiolabeled ligand based assay,Confirmatory,18083578.0,
309,328611,3,3,,103190535,5816,Active,,,,,Induction of M6P receptor-mediated brain uptake of [131I]phosphorylated beta-glucuronidase from serum in iv dosed CD1 mouse after 5 mins,Other,17646643.0,
310,328612,3,3,,103190535,5816,Active,,,,,"Induction of brain uptake of [125I]albumin from serum in CD1 mouse at 120 nmol, iv after 5 mins",Other,17646643.0,
311,328613,6,1,,103190535,5816,Unspecified,,,,,"Increase in M6P receptor-mediated brain to brain influx rate of [131I]phosphorylated beta-glucuronidase in CD1 mouse at 12 nmol, iv",Other,17646643.0,
312,328614,6,1,,103190535,5816,Unspecified,,,,,"Increase in M6P receptor-mediated brain to brain influx rate of [131I]phosphorylated beta-glucuronidase in CD1 mouse at 40 nmol, iv",Other,17646643.0,
313,328615,6,1,,103190535,5816,Unspecified,,,,,"Increase in M6P receptor-mediated brain to brain influx rate of [131I]phosphorylated beta-glucuronidase in CD1 mouse at 120 nmol, iv",Other,17646643.0,
314,328616,3,3,,103190535,5816,Inactive,,,,,"Increase in brain to brain influx rate of [125I]albumin in CD1 mouse at 120 nmol, iv",Other,17646643.0,
315,328617,3,3,,103190535,5816,Inactive,,,,,"Increase in brain to brain influx rate of [125I]albumin in CD1 mouse at 40 nmol, iv",Other,17646643.0,
316,328618,3,3,,103190535,5816,Unspecified,,,,,"Induction of M6P receptor-mediated brain uptake of [131I]phosphorylated beta-glucuronidase in CD1 mouse assessed as parenchymal level at 40 nmol, iv after 10 mins",Other,17646643.0,
317,328619,3,3,,103190535,5816,Unspecified,,,,,"Induction of M6P receptor mediated brain uptake of [131I]phosphorylated beta-glucuronidase in CD1 mouse assessed as capillary fraction level at 40 nmol, iv after 10 mins",Other,17646643.0,
318,328620,3,3,,103190535,5816,Unspecified,,,,,"Induction of brain uptake of [131I]phosphorylated beta-glucuronidase in beta-glucuronidase deficient mucopolysaccharidosis type VII mouse at 40 nmol, iv after 24 hrs",Other,17646643.0,
319,328621,3,3,,103190535,5816,Active,,,,,Reversal of induction of M6P receptor-mediated brain uptake of [131I]phosphorylated beta-glucuronidase in iv dosed CD1 mouse in presence of mannose 6-phosphate,Other,17646643.0,
320,328622,3,3,,103190535,5816,Inactive,,,,,"Induction of M6P receptor-mediated brain uptake of [131I]non-phosphorylated beta-glucuronidase in iv dosed CD1 mouse at 40 nmol, iv after 10 mins",Other,17646643.0,
321,328623,3,3,,103190535,5816,Active,,,,,"Induction of M6P receptor-mediated uptake of [131I]phosphorylated beta-glucuronidase in CD1 mouse heart at 40 nmol, iv after 10 mins",Other,17646643.0,
322,328624,3,3,,103190535,5816,Inactive,,,,,"Induction of M6P receptor-mediated uptake of [131I]phosphorylated beta-glucuronidase in CD1 mouse liver at 40 nmol, iv after 10 mins",Other,17646643.0,
323,328625,3,3,,103190535,5816,Active,,,,,"Reversal of induction of M6P receptor-mediated uptake of [131I]phosphorylated beta-glucuronidase in CD1 mouse heart at 40 nmol, iv in presence of mannose 6-phosphate after 10 mins",Other,17646643.0,
324,386623,4,8,,103190535,5816,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
325,392783,7,1,,103190535,5816,Unspecified,,,,,Binding interaction with fibrinogen assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment,Other,19157885.0,
326,392784,6,1,,103190535,5816,Unspecified,,,,,Binding interaction with platelet assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment,Other,19157885.0,
327,401519,6,2,,103190535,5816,Active,,,0.16,Ki,Displacement of radioligand from rat alpha2 adrenergic receptor by liquid scintillation spectrometry,Confirmatory,9182127.0,
328,426242,12,2,,103190535,5816,Active,296439450.0,154.0,0.63,Kd,Binding affinity to human adrenergic beta2 receptor,Confirmatory,19168263.0,
329,455986,3,5,,103190535,5816,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
330,463106,1,2,,90341589,5816,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
331,485281,1,1,,26754419,5816,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
332,485281,1,1,,26754420,5816,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
333,485281,1,1,,29215202,5816,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
334,485290,1,1,,26754418,5816,Inconclusive,20150581.0,,3.1623,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
335,485290,1,1,,26754419,5816,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
336,485290,1,1,,26754420,5816,Inconclusive,20150581.0,,3.5481,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
337,485290,1,1,,29215202,5816,Inconclusive,20150581.0,,0.7943,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
338,485295,1,2,,90341589,5816,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
339,485297,1,1,,90341589,5816,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
340,485298,1,1,,90341589,5816,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
341,485313,1,2,,90341589,5816,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
342,485342,1,2,,90341589,5816,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
343,485345,1,2,,90341589,5816,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
344,485366,1,2,,90341589,5816,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
345,485368,1,2,,90341589,5816,Inconclusive,72386991.0,3656265.0,33.8078,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
346,488772,1,1,,90341589,5816,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
347,488773,1,2,,90341589,5816,Inconclusive,8659577.0,58819.0,21.1923,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
348,488816,1,1,,90341589,5816,Active,4758356.0,2237.0,10.6213,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
349,488837,1,1,,90341589,5816,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
350,488949,1,2,,90341589,5816,Inconclusive,41055989.0,54737.0,37.6858,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
351,488953,1,1,,90341589,5816,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
352,488978,1,1,,90341589,5816,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
353,488981,1,1,,90341589,5816,Inconclusive,4503383.0,1812.0,3.1623,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
354,488982,1,1,,90341589,5816,Inactive,4503383.0,1812.0,0.4109,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
355,488983,1,1,,90341589,5816,Active,4503383.0,1812.0,2.5119,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
356,492961,1,1,,29215202,5816,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
357,493106,1,1,,90341589,5816,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
358,493107,1,1,,90341589,5816,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
359,493153,1,1,,90341589,5816,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
360,493153,1,1,,90341589,5816,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
361,493164,1,2,,90341589,5816,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
362,493164,1,2,,90341589,5816,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
363,493164,1,2,,90341589,5816,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
364,496772,2,4,,103190535,5816,Active,,,,,Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening,Other,20081854.0,
365,504327,1,1,,26754418,5816,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
366,504327,1,1,,26754419,5816,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
367,504327,1,1,,26754420,5816,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
368,504327,1,1,,29215202,5816,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
369,504327,1,1,,90341589,5816,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
370,504332,1,1,,26754419,5816,Inconclusive,168985070.0,,0.7943,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
371,504332,1,1,,29215202,5816,Inconclusive,168985070.0,,6.3096,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
372,504332,1,1,,90341589,5816,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
373,504536,1,1,,90341589,5816,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
374,504547,1,1,,90341589,5816,Inconclusive,115503961.0,4357161.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
375,504548,1,2,,90341589,5816,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
376,504749,1,3,,29215202,5816,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
377,504749,1,3,1.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
378,504749,1,3,2.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
379,504749,1,3,3.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
380,504749,1,3,4.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
381,504749,1,3,5.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
382,504749,1,3,6.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
383,504749,1,3,7.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
384,504749,1,3,8.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
385,504749,1,3,9.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
386,504749,1,3,10.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
387,504749,1,3,11.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
388,504749,1,3,12.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
389,504749,1,3,13.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
390,504749,1,3,14.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
391,504749,1,3,15.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
392,504749,1,3,16.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
393,504749,1,3,17.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
394,504749,1,3,18.0,29215202,5816,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
395,504749,1,3,19.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
396,504749,1,3,20.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
397,504749,1,3,21.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
398,504749,1,3,22.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
399,504749,1,3,23.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
400,504749,1,3,24.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
401,504749,1,3,25.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
402,504749,1,3,26.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
403,504749,1,3,27.0,29215202,5816,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
404,504749,1,3,28.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
405,504749,1,3,29.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
406,504749,1,3,30.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
407,504749,1,3,31.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
408,504749,1,3,32.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
409,504749,1,3,33.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
410,504749,1,3,34.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
411,504749,1,3,35.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
412,504749,1,3,36.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
413,504749,1,3,37.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
414,504749,1,3,38.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
415,504749,1,3,39.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
416,504749,1,3,40.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
417,504749,1,3,41.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
418,504749,1,3,42.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
419,504749,1,3,43.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
420,504749,1,3,44.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
421,504749,1,3,45.0,29215202,5816,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
422,504749,1,3,46.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
423,504749,1,3,47.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
424,504749,1,3,48.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
425,504749,1,3,49.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
426,504749,1,3,50.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
427,504749,1,3,51.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
428,504749,1,3,52.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
429,504749,1,3,53.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
430,504749,1,3,54.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
431,504749,1,3,55.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
432,504749,1,3,56.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
433,504749,1,3,57.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
434,504749,1,3,58.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
435,504749,1,3,59.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
436,504749,1,3,60.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
437,504749,1,3,61.0,29215202,5816,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
438,504810,1,2,,90341589,5816,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
439,504812,1,2,,90341589,5816,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
440,504832,1,1,,29215202,5816,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
441,504834,1,1,,29215202,5816,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
442,504836,1,2,,90341589,5816,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
443,504845,1,1,,26754418,5816,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
444,504845,1,1,,26754419,5816,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
445,504845,1,1,,90341589,5816,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
446,504847,1,1,,26754418,5816,Active,63054845.0,7421.0,31.6228,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
447,504847,1,1,,26754419,5816,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
448,504847,1,1,,26754420,5816,Inconclusive,63054845.0,7421.0,79.4328,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
449,504847,1,1,,29215202,5816,Inconclusive,63054845.0,7421.0,50.1187,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
450,504847,1,1,,90341589,5816,Inconclusive,63054845.0,7421.0,50.1187,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
451,504865,1,1,,26754418,5816,Inconclusive,118600387.0,7398.0,63.0957,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
452,504865,1,1,,29215202,5816,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
453,504865,1,1,,90341589,5816,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
454,513146,4,2,,103190535,5816,Active,,,0.11,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
455,513148,2,3,,103190535,5816,Unspecified,,,,,Agonist activity at human Beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as decrease in bimane fluorescence intensity by fluorescence spectroscopy,Other,16799554.0,
456,513152,2,3,,103190535,5816,Unspecified,,,,,Partial agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy,Other,16799554.0,
457,513154,4,2,,103190535,5816,Active,,,0.1,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271/W135 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
458,540256,1,2,,90341589,5816,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
459,540276,1,2,,11111154,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
460,540276,1,2,,26754418,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
461,540276,1,2,,26754419,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
462,540276,1,2,,26754420,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
463,540276,1,2,,29215202,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
464,540276,1,2,,50109837,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
465,540276,1,2,,90341589,5816,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
466,588211,2,3,,103190535,5816,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
467,588212,2,3,,103190535,5816,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
468,588213,2,3,,103190535,5816,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
469,588220,2,3,,103190535,5816,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
470,588349,1,1,,90341589,5816,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
471,588378,1,1,,90341589,5816,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
472,588379,1,2,,26754418,5816,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
473,588453,1,1,,90341589,5816,Inconclusive,8659577.0,58819.0,21.1923,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
474,588456,1,1,,90341589,5816,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
475,588513,1,1,,26754420,5816,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
476,588514,1,1,,26754420,5816,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
477,588515,1,1,,26754420,5816,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
478,588516,1,1,,26754420,5816,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
479,588526,1,1,,26754420,5816,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
480,588527,1,1,,26754420,5816,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
481,588532,1,1,,26754420,5816,Inconclusive,311348376.0,2908.0,28.1838,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
482,588533,1,1,,26754420,5816,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
483,588534,1,1,,26754420,5816,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
484,588535,1,1,,26754420,5816,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
485,588536,1,1,,26754420,5816,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
486,588537,1,1,,26754420,5816,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
487,588541,1,1,,26754420,5816,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
488,588543,1,1,,26754420,5816,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
489,588544,1,1,,26754420,5816,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
490,588545,1,1,,26754420,5816,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
491,588546,1,1,,26754420,5816,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
492,588547,1,1,,26754420,5816,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
493,588579,1,1,,26754418,5816,Active,7705344.0,51426.0,1.9953,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
494,588579,1,1,,26754419,5816,Inconclusive,7705344.0,51426.0,11.2202,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
495,588579,1,1,,26754420,5816,Active,7705344.0,51426.0,2.6679,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
496,588579,1,1,,29215202,5816,Active,7705344.0,51426.0,7.0795,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
497,588579,1,1,,90341589,5816,Inconclusive,7705344.0,51426.0,26.6795,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
498,588795,1,1,,90341589,5816,Active,4758356.0,2237.0,10.6213,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
499,588834,2,1,,29215202,5816,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
500,592681,1,4,,103190535,5816,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
501,602332,1,1,,26754418,5816,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
502,602332,1,1,,26754419,5816,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
503,602332,1,1,,26754420,5816,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
504,602332,1,1,,29215202,5816,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
505,602332,1,1,,90341589,5816,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
506,624030,1,2,,29215202,5816,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
507,624031,1,2,,29215202,5816,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
508,624032,1,2,,29215202,5816,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
509,624044,1,2,,29215202,5816,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
510,624146,1,1,,90341589,5816,Inactive,71051501.0,2744.0,11.2202,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
511,624147,1,1,,90341589,5816,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
512,624148,1,2,,90341589,5816,Inconclusive,1724069.0,2740.0,2.5929,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
513,624149,1,1,,90341589,5816,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
514,624170,1,1,,29215202,5816,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
515,624172,1,1,,29215202,5816,Inconclusive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
516,624173,1,3,,29215202,5816,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
517,624296,1,1,,29215202,5816,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
518,624297,1,1,,29215202,5816,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
519,624455,1,1,,90341589,5816,Active,299681.0,1812.0,0.1636,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
520,625144,5,5,,103190535,5816,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
521,625145,4,7,,103190535,5816,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
522,625146,5,5,,103190535,5816,Active,126397.0,100009114.0,3.279,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
523,625147,4,7,,103190535,5816,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
524,625148,4,7,,103190535,5816,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
525,625149,4,7,,103190535,5816,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
526,625150,5,5,,103190535,5816,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
527,625151,4,7,,103190535,5816,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
528,625152,4,7,,103190535,5816,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
529,625153,4,7,,103190535,5816,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
530,625154,4,7,,103190535,5816,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
531,625155,4,7,,103190535,5816,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
532,625156,1,9,,103190535,5816,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
533,625157,6,2,,103190535,5816,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
534,625158,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
535,625159,5,5,,103190535,5816,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
536,625160,1,9,,103190535,5816,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
537,625161,4,7,,103190535,5816,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
538,625162,4,7,,103190535,5816,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
539,625163,4,7,,103190535,5816,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
540,625164,1,6,,103190535,5816,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
541,625165,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
542,625166,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
543,625167,5,5,,103190535,5816,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
544,625168,4,7,,103190535,5816,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
545,625169,1,6,,103190535,5816,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
546,625170,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
547,625171,4,7,,103190535,5816,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
548,625172,4,7,,103190535,5816,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
549,625173,5,5,,103190535,5816,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
550,625174,5,5,,103190535,5816,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
551,625175,5,5,,103190535,5816,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
552,625176,1,9,,103190535,5816,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
553,625177,5,5,,103190535,5816,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
554,625178,5,5,,103190535,5816,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
555,625179,1,9,,103190535,5816,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
556,625180,5,5,,103190535,5816,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
557,625181,5,5,,103190535,5816,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
558,625182,5,5,,103190535,5816,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
559,625183,5,5,,103190535,5816,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
560,625184,5,5,,103190535,5816,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
561,625185,5,5,,103190535,5816,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
562,625186,5,5,,103190535,5816,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
563,625187,5,5,,103190535,5816,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
564,625188,1,9,,103190535,5816,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
565,625189,1,7,,103190535,5816,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
566,625190,4,5,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
567,625191,4,7,,103190535,5816,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
568,625192,4,7,,103190535,5816,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
569,625193,5,5,,103190535,5816,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
570,625194,4,7,,103190535,5816,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
571,625195,4,7,,103190535,5816,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
572,625196,5,6,,103190535,5816,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
573,625197,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
574,625198,4,7,,103190535,5816,Active,1168247.0,29412.0,0.628,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
575,625199,4,7,,103190535,5816,Active,543734.0,24173.0,1.766,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
576,625200,4,7,,103190535,5816,Active,1168243.0,146.0,0.449,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
577,625201,4,7,,103190535,5816,Active,1351829.0,150.0,0.737,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
578,625202,4,7,,103190535,5816,Active,613504690.0,151.0,0.8690000000000001,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
579,625203,4,7,,103190535,5816,Active,20141211.0,152.0,2.449,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
580,625204,4,7,,103190535,5816,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
581,625205,4,7,,103190535,5816,Active,296439450.0,154.0,0.284,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
582,625206,4,7,,103190535,5816,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
583,625207,4,7,,103190535,5816,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
584,625208,5,5,,103190535,5816,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
585,625209,4,7,,103190535,5816,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
586,625210,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
587,625211,1,6,,103190535,5816,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
588,625212,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
589,625213,4,7,,103190535,5816,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
590,625214,1,9,,103190535,5816,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
591,625215,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
592,625216,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
593,625217,4,7,,103190535,5816,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
594,625218,4,7,,103190535,5816,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
595,625219,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
596,625220,4,7,,103190535,5816,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
597,625221,4,7,,103190535,5816,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
598,625222,4,7,,103190535,5816,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
599,625223,4,7,,103190535,5816,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
600,625224,3,4,,103190535,5816,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
601,625225,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
602,625226,4,7,,103190535,5816,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
603,625227,4,7,,103190535,5816,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
604,625228,4,7,,103190535,5816,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
605,625229,5,5,,103190535,5816,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
606,625230,1,6,,103190535,5816,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
607,625231,4,7,,103190535,5816,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
608,625232,1,9,,103190535,5816,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
609,625233,4,7,,103190535,5816,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
610,625234,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
611,625235,4,7,,103190535,5816,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
612,625236,5,5,,103190535,5816,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
613,625237,4,7,,103190535,5816,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
614,625238,4,7,,103190535,5816,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
615,625239,4,7,,103190535,5816,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
616,625240,1,9,,103190535,5816,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
617,625241,4,7,,103190535,5816,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
618,625242,4,7,,103190535,5816,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
619,625243,5,5,,103190535,5816,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
620,625244,5,5,,103190535,5816,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
621,625245,5,5,,103190535,5816,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
622,625246,1,9,,103190535,5816,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
623,625247,5,5,,103190535,5816,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
624,625248,5,5,,103190535,5816,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
625,625249,5,5,,103190535,5816,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
626,625250,5,5,,103190535,5816,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
627,625251,5,5,,103190535,5816,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
628,625252,4,7,,103190535,5816,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
629,625253,4,7,,103190535,5816,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
630,625254,4,7,,103190535,5816,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
631,625255,4,7,,103190535,5816,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
632,625256,4,7,,103190535,5816,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
633,625257,4,7,,103190535,5816,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
634,625258,4,7,,103190535,5816,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
635,625259,4,7,,103190535,5816,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
636,625260,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
637,625261,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
638,625262,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
639,625263,4,7,,103190535,5816,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
640,625264,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
641,625265,1,6,,103190535,5816,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
642,625266,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
643,625267,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
644,625268,4,2,,103190535,5816,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
645,625268,4,2,,103190535,5816,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
646,625268,4,2,,103190535,5816,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
647,625268,4,2,,103190535,5816,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
648,625269,4,7,,103190535,5816,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
649,625270,4,7,,103190535,5816,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
650,625271,5,5,,103190535,5816,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
651,625272,3,4,,103190535,5816,Active,,,0.23199999999999998,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
652,625273,4,6,,103190535,5816,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
653,625274,1,6,,103190535,5816,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
654,625275,3,4,,103190535,5816,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
655,625278,1,3,,103190535,5816,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI,Other,21624500.0,
656,625279,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
657,625280,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
658,625281,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
659,625282,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
660,625283,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
661,625284,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
662,625285,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
663,625286,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
664,625287,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
665,625288,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
666,625289,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
667,625290,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
668,625291,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
669,625292,1,3,,103190535,5816,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
670,651631,4,1,,144205115,5816,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
671,651632,4,1,,144205115,5816,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
672,651633,4,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
673,651634,4,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
674,651635,1,3,,90341589,5816,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
675,651741,1,1,,26754420,5816,Active,20149576.0,4780.0,48.5577,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
676,651743,1,1,,26754420,5816,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
677,651749,1,1,,26754420,5816,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
678,651751,1,1,,26754420,5816,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
679,651777,1,1,,26754420,5816,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
680,651778,1,1,,26754420,5816,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
681,651838,1,1,,26754420,5816,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
682,651838,1,1,1.0,26754420,5816,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
683,651838,1,1,2.0,26754420,5816,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
684,651838,1,1,3.0,26754420,5816,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
685,651838,1,1,4.0,26754420,5816,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
686,651838,1,1,5.0,26754420,5816,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
687,651838,1,1,6.0,26754420,5816,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
688,651838,1,1,7.0,26754420,5816,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
689,651838,1,1,8.0,26754420,5816,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
690,652048,1,2,,144205115,5816,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
691,652051,1,1,,144205115,5816,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
692,652106,1,1,,90341589,5816,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
693,680541,1,7,,103190535,5816,Unspecified,8928277.0,20520.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Epinephrine: 5000 uM) in OCTN2-expressing HEK293 cells",Other,11160873.0,
694,681368,3,6,,103190535,5816,Unspecified,81872789.0,29503.0,1191.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells,Confirmatory,11758759.0,
695,681375,3,6,,103190535,5816,Unspecified,81872095.0,24904.0,1600.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells,Confirmatory,11758759.0,
696,681565,2,7,,103190535,5816,Unspecified,81872789.0,29503.0,1900.0,Km,TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells,Confirmatory,9812985.0,
697,681601,1,7,,103190535,5816,Unspecified,81872095.0,24904.0,,,TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells,Other,9776363.0,
698,686978,1,1,,26754418,5816,Active,79154014.0,55775.0,11.8856,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
699,686978,1,1,,26754419,5816,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
700,686978,1,1,,144205115,5816,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
701,686979,1,1,,26754418,5816,Active,79154014.0,55775.0,8.4144,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
702,686979,1,1,,26754419,5816,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
703,686979,1,1,,144205115,5816,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
704,720516,2,1,,144205115,5816,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
705,720532,1,1,,26754418,5816,Active,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
706,720532,1,1,,26754419,5816,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
707,720532,1,1,,26754420,5816,Active,420597.0,,7.9433,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
708,720532,1,1,,144205115,5816,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
709,720533,1,1,,26754418,5816,Inconclusive,,,19.9526,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
710,720533,1,1,,26754419,5816,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
711,720533,1,1,,26754420,5816,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
712,720533,1,1,,144205115,5816,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
713,720538,1,2,,90341589,5816,Inconclusive,220983390.0,410.0,0.0135,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
714,720552,2,1,,144205115,5816,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
715,720559,1,2,,90341589,5816,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
716,720572,1,2,,90341589,5816,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
717,720573,1,2,,90341589,5816,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
718,720579,2,1,,26754419,5816,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
719,720580,1,1,,26754419,5816,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
720,720634,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
721,720635,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
722,720636,1,1,,26754420,5816,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
723,720637,2,1,,144205115,5816,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
724,720653,1,1,,26754420,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
725,720659,1,1,,26754420,5816,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
726,720674,2,2,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
727,720675,2,2,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
728,720678,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
729,720679,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
730,720680,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
731,720681,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
732,720682,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
733,720683,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
734,720684,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
735,720685,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
736,720686,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
737,720687,2,2,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
738,720691,4,1,,144205115,5816,Inactive,311348376.0,2908.0,0.5354,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
739,720692,3,1,,144205115,5816,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
740,720693,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
741,720719,2,1,,144205115,5816,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
742,720725,2,1,,144205115,5816,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
743,743012,3,1,,144205115,5816,Active,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
744,743014,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
745,743015,3,1,,144205115,5816,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
746,743033,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
747,743035,2,1,,144205115,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
748,743036,2,1,,144205115,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
749,743040,3,1,,144205115,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
750,743041,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
751,743042,3,1,,144205115,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
752,743053,2,1,,144205115,5816,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
753,743054,2,1,,144205115,5816,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
754,743063,2,1,,144205115,5816,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
755,743064,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
756,743065,3,1,,144205115,5816,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
757,743066,3,1,,144205115,5816,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
758,743067,2,1,,144205115,5816,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
759,743069,2,1,,144205115,5816,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
760,743074,2,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
761,743075,2,1,,144205115,5816,Inactive,348019627.0,2099.0,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
762,743077,2,1,,144205115,5816,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
763,743078,2,1,,144205115,5816,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
764,743079,3,1,,144205115,5816,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
765,743080,3,1,,144205115,5816,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
766,743081,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
767,743083,3,1,,144205115,5816,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
768,743084,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
769,743085,3,1,,144205115,5816,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
770,743086,3,1,,144205115,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
771,743091,2,1,,144205115,5816,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
772,743094,3,1,,144205115,5816,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
773,743122,2,1,,144205115,5816,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
774,743139,2,1,,144205115,5816,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
775,743140,2,1,,144205115,5816,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
776,743191,3,1,,170464973,5816,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
777,743194,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
778,743199,2,1,,170464973,5816,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
779,743202,4,1,,170464973,5816,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
780,743203,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
781,743205,1,1,,90341589,5816,Inactive,4503951.0,2645.0,2.8184,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
782,743205,1,1,,90341589,5816,Inactive,221625433.0,2646.0,2.8184,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
783,743206,1,1,,90341589,5816,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
784,743206,1,1,,90341589,5816,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
785,743207,1,1,,90341589,5816,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
786,743207,1,1,,90341589,5816,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
787,743209,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
788,743210,4,1,,170464973,5816,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
789,743211,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
790,743212,3,1,,170464973,5816,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
791,743213,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
792,743215,3,1,,170464973,5816,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
793,743217,3,1,,170464973,5816,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
794,743218,3,1,,170464973,5816,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
795,743219,3,1,,170464973,5816,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
796,743220,3,1,,170464973,5816,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
797,743221,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
798,743222,3,1,,170464973,5816,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
799,743223,3,1,,170464973,5816,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
800,743224,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
801,743225,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
802,743226,2,1,,170464973,5816,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
803,743227,2,1,,170464973,5816,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
804,743228,3,1,,170464973,5816,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
805,743239,2,1,,170464973,5816,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
806,743240,2,1,,170464973,5816,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
807,743241,2,1,,170464973,5816,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
808,743242,2,1,,170464973,5816,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
809,743244,1,1,,90341589,5816,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
810,743244,1,1,,144205115,5816,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
811,743262,1,1,,144205115,5816,Inconclusive,1724069.0,2740.0,0.0251,Potency,qHTS of GLP-1 Receptor Agonists: Hit Validation,Confirmatory,,
812,743288,1,1,,26754420,5816,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
813,743292,1,1,,26754420,5816,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
814,743344,1,1,,29215202,5816,Inactive,,,27.2824,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
815,743345,1,1,,29215202,5816,Inactive,,,27.2824,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
816,743346,1,1,,29215202,5816,Inactive,,,21.6712,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
817,743347,1,1,,29215202,5816,Inactive,,,21.6712,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
818,770362,2,3,,103190535,5816,Active,296439450.0,154.0,0.6309600000000001,Kd,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,Confirmatory,23954364.0,
819,926850,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021028,Other,,
820,926851,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021028,Other,,
821,926852,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021028,Other,,
822,926853,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021028,Other,,
823,926854,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021028,Other,,
824,926855,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021028,Other,,
825,926856,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021028,Other,,
826,926857,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021028,Other,,
827,926858,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021028",Other,,
828,926859,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021028,Other,,
829,926860,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021028,Other,,
830,926861,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021028,Other,,
831,926862,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021028,Other,,
832,926863,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021028,Other,,
833,926864,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021028,Other,,
834,926865,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021028,Other,,
835,928866,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021028,Other,,
836,928867,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021028,Other,,
837,928868,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021028,Other,,
838,939959,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021028,Other,,
839,939960,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021028",Other,,
840,939961,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021028,Other,,
841,939962,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021028,Other,,
842,939963,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021028,Other,,
843,939964,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021028,Other,,
844,939965,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021028,Other,,
845,939966,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021028,Other,,
846,939967,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021028,Other,,
847,939968,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021028,Other,,
848,939969,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021028,Other,,
849,939970,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021028,Other,,
850,939971,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021028,Other,,
851,939972,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021028,Other,,
852,939973,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021028,Other,,
853,939974,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021028,Other,,
854,939975,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021028,Other,,
855,939976,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021028,Other,,
856,942625,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021028,Other,,
857,958721,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021028,Other,,
858,958722,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021028,Other,,
859,958723,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021028,Other,,
860,958724,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021028,Other,,
861,958725,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021028,Other,,
862,958726,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021028,Other,,
863,958727,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021028,Other,,
864,958728,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021028,Other,,
865,958729,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021028,Other,,
866,958730,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021028,Other,,
867,958731,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021028,Other,,
868,958732,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021028,Other,,
869,958733,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021028,Other,,
870,958734,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021028,Other,,
871,958735,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021028,Other,,
872,958736,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021028,Other,,
873,958737,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021028,Other,,
874,958738,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021028,Other,,
875,958739,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021028,Other,,
876,977060,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021028,Other,,
877,977061,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021028,Other,,
878,977062,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021028,Other,,
879,977063,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021028,Other,,
880,977064,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021028,Other,,
881,977065,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021028,Other,,
882,977066,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021028,Other,,
883,977067,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021028,Other,,
884,977068,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021028,Other,,
885,977069,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021028,Other,,
886,977070,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021028,Other,,
887,977071,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021028,Other,,
888,977072,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021028,Other,,
889,977073,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021028,Other,,
890,977074,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021028,Other,,
891,977075,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021028,Other,,
892,977076,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021028,Other,,
893,977077,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021028,Other,,
894,977078,1,3,,103190535,5816,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021028,Other,,
895,1007734,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
896,1007735,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
897,1007736,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S021028",Other,,
898,1007737,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S021028",Other,,
899,1007738,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
900,1007739,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S021028",Other,,
901,1014469,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
902,1014470,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
903,1014471,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S021028",Other,,
904,1014472,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S021028",Other,,
905,1014473,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S021028",Other,,
906,1014474,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S021028",Other,,
907,1014475,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S021028",Other,,
908,1014476,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
909,1014477,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
910,1014478,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S021028",Other,,
911,1014479,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
912,1014480,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S021028",Other,,
913,1014481,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S021028",Other,,
914,1014482,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
915,1014483,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S021028",Other,,
916,1014484,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
917,1014485,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
918,1014486,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021028",Other,,
919,1014487,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S021028",Other,,
920,1014488,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S021028",Other,,
921,1014489,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
922,1014490,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
923,1014491,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S021028",Other,,
924,1014492,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S021028",Other,,
925,1014493,1,3,,103190535,5816,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021028",Other,,
926,1117298,1,2,,170464973,5816,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
927,1117304,1,2,,170464973,5816,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
928,1117305,1,2,,170464973,5816,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
929,1117310,1,1,,170464973,5816,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
930,1117312,1,1,,170464973,5816,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
931,1117314,1,1,,170464973,5816,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
932,1117326,1,1,,170464973,5816,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
933,1117329,1,1,,170464973,5816,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
934,1117336,1,1,,170464973,5816,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
935,1117340,1,1,,170464973,5816,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
936,1117341,1,1,,170464973,5816,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
937,1117342,1,1,,170464973,5816,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
938,1117343,1,1,,170464973,5816,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
939,1117346,1,1,,170464973,5816,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
940,1132810,1,1,,103190535,5816,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,671451.0,
941,1132811,1,2,,103190535,5816,Unspecified,,,,,Acute pressor activity in iv dosed Sprague-Dawley rat assessed as dose required to increase arterial systolic blood pressure by 30 mmHg,Other,671451.0,
942,1132812,1,2,,103190535,5816,Unspecified,,,,,Acute pressor activity in iv dosed Sprague-Dawley rat assessed as dose required to increase arterial systolic blood pressure by 30 mmHg relative to dopamine,Other,671451.0,
943,1132813,1,2,,103190535,5816,Unspecified,,,,,Acute pressor activity in iv dosed Sprague-Dawley rat assessed as duration of arterial systolic blood pressure by 30 mmHg maintenance,Other,671451.0,
944,1136027,1,1,,103190535,5816,Unspecified,,,,,Stimulation of guinea pig lung adenylate cyclase activity at 1 x 10'-4 M after 15 mins relative to control,Other,229222.0,
945,1136412,1,1,,103190535,5816,Unspecified,,,,,Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes,Other,31486.0,
946,1136413,1,1,,103190535,5816,Unspecified,,,,,Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes relative to isoproterenol,Other,31486.0,
947,1144251,1,3,,103190535,5816,Unspecified,116909.0,24267.0,,Km,Activity of Sprague-Dawley rat liver COMT using [14CH3]-SAM as methyl group donor after 10 mins by scintillation spectrophotometric analysis,Confirmatory,1246034.0,
948,1159509,1,1,,170464973,5816,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
949,1159515,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
950,1159516,1,1,,170464973,5816,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
951,1159517,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
952,1159518,1,1,,170464973,5816,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
953,1159519,1,1,,170464973,5816,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
954,1159520,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
955,1159521,1,1,,170464973,5816,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
956,1159523,1,1,,170464973,5816,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
957,1159524,1,1,,26754419,5816,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
958,1159525,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
959,1159526,1,1,,170464973,5816,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
960,1159527,1,1,,170464973,5816,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
961,1159528,1,1,,170464973,5816,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
962,1159529,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
963,1159531,1,1,,170464973,5816,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
964,1159551,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
965,1159552,1,1,,170464973,5816,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
966,1159553,2,1,,170464973,5816,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
967,1159555,1,1,,170464973,5816,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
968,1159580,2,1,,268738126,5816,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
969,1159607,2,1,,313041532,5816,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
970,1159614,1,2,,170464973,5816,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
971,1159620,1,1,,103190535,5816,Active,,,,,Summary of drug indications.,Other,,
972,1223488,1,1,,103190535,5816,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
973,1223490,1,1,,103190535,5816,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
974,1224824,1,1,,29215202,5816,Inactive,,,24.1005,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
975,1224825,1,1,,29215202,5816,Inactive,,,15.2064,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
976,1224834,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
977,1224835,1,1,,170464973,5816,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
978,1224836,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
979,1224837,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
980,1224838,1,1,,170464973,5816,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
981,1224839,1,1,,170464973,5816,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
982,1224840,3,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
983,1224841,3,1,,170464973,5816,Inactive,325495545.0,2101.0,1.0318,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
984,1224842,3,1,,170464973,5816,Active,325495545.0,2101.0,1.1577,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
985,1224843,1,1,,170464973,5816,Active,119601739.0,7253.0,2.31,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
986,1224844,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
987,1224845,1,1,,170464973,5816,Inconclusive,344243002.0,100757539.0,2.4026,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
988,1224846,1,1,,170464973,5816,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
989,1224847,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
990,1224848,3,1,,170464973,5816,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
991,1224849,3,1,,170464973,5816,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
992,1224857,2,1,,29215202,5816,Inconclusive,,,53.9544,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
993,1224857,2,1,,170464973,5816,Inconclusive,,,3.5481,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
994,1224859,2,1,,29215202,5816,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
995,1224859,2,1,,90341589,5816,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
996,1224859,2,1,,170464973,5816,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
997,1224863,1,1,,176484035,5816,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
998,1224863,1,1,,176485032,5816,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
999,1224863,1,1,,176485081,5816,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1000,1224867,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1001,1224868,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1002,1224869,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1003,1224870,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1004,1224871,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1005,1224872,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1006,1224873,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1007,1224874,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1008,1224875,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1009,1224876,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1010,1224877,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1011,1224878,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1012,1224879,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1013,1224880,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1014,1224881,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1015,1224882,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1016,1224883,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1017,1224884,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1018,1224885,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1019,1224886,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1020,1224887,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1021,1224888,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1022,1224889,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1023,1224890,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1024,1224892,1,1,,170464973,5816,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1025,1224893,1,1,,170464973,5816,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1026,1224894,1,1,,170464973,5816,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1027,1224895,1,1,,170464973,5816,Active,119601739.0,7253.0,2.13932,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1028,1224896,1,1,,170464973,5816,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1029,1259241,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1030,1259242,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1031,1259243,1,1,,170464973,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1032,1259244,1,1,,170464973,5816,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1033,1259247,1,1,,170464973,5816,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1034,1259248,1,1,,170464973,5816,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1035,1259252,1,1,,29215202,5816,Active,169655958.0,,42.8575,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1036,1259253,1,1,,29215202,5816,Inconclusive,169655958.0,,34.0429,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1037,1259255,1,1,,29215202,5816,Inconclusive,169655958.0,,76.2126,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1038,1259256,1,1,,29215202,5816,Active,169655958.0,,38.1968,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1039,1259344,1,1,,144205115,5816,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1040,1259355,1,1,,29215202,5816,Inconclusive,,,35.4813,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1041,1259356,1,1,,29215202,5816,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1042,1259364,1,1,,170464973,5816,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1043,1259365,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1044,1259366,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1045,1259367,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1046,1259368,1,1,,170464973,5816,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1047,1259369,1,1,,170464973,5816,Inactive,109731339.0,2737.0,5.8024,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1048,1259377,1,1,,170464973,5816,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1049,1259378,1,1,,170464973,5816,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1050,1259379,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1051,1259380,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1052,1259381,1,1,,170464973,5816,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1053,1259382,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1054,1259383,1,1,,170464973,5816,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1055,1259384,1,1,,170464973,5816,Active,,,0.2908,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1056,1259385,1,1,,170464973,5816,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1057,1259386,1,1,,170464973,5816,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1058,1259387,1,1,,170464973,5816,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1059,1259388,1,1,,170464973,5816,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1060,1259390,1,1,,170464973,5816,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1061,1259391,1,1,,170464973,5816,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1062,1259392,1,1,,170464973,5816,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1063,1259393,1,1,,170464973,5816,Active,119601739.0,7253.0,0.11141500000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1064,1259394,1,1,,170464973,5816,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1065,1259395,1,1,,170464973,5816,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1066,1259396,1,1,,170464973,5816,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1067,1259400,1,1,,124892089,5816,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1068,1259401,1,1,,170464973,5816,Inconclusive,325495545.0,2101.0,0.676513,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1069,1259402,1,1,,170464973,5816,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1070,1259403,1,1,,170464973,5816,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1071,1259404,1,1,,170464973,5816,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1072,1259407,1,1,,363902762,5816,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1073,1259408,1,1,,363894785,5816,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
1074,1259409,1,1,,363902762,5816,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1075,1259416,1,2,,340080772,5816,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1076,1259421,1,1,,340080772,5816,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1077,1259423,1,2,,354784333,5816,Active,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1078,1259426,1,2,,354784333,5816,Active,550600288.0,5570400.0,0.039,EC50_MICROM,Counter Screen to Identify Specific Small molecule Agonists for Aedes aegypti NPYLR7 Receptor,Confirmatory,,
1079,1259427,1,2,,354784333,5816,Inactive,,,0.078,EC50_MICROM,Hit Validation Assay to Identify small molecule Aedes aegypti NPYLR7 Agonists [Small Molecule Inhibitors of Mosquito Biting Behavior],Confirmatory,,
